# Qilu Pharmaceutical Co., Ltd.: Phase 3 study started recruiting, 556 planned (Extensive-stage Small Cell Lung Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer |
| NCT ID | NCT07802821 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Extensive-stage Small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 556 |
| Site countries | China |
| Posted | 2026-09-03 |
| Planned start | 2026-10-27 |
| Event | Started recruiting |
| Event date | 2026-10-27 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 556 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07802821). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.